Equities

LifeMD Inc

LFMD:NMQ

LifeMD Inc

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (USD)5.28
  • Today's Change0.04 / 0.76%
  • Shares traded306.82k
  • 1 Year change+19.73%
  • Beta1.1976
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform6
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for LifeMD Inc have a median target of 12.00, with a high estimate of 16.00 and a low estimate of 10.00. The median estimate represents a 127.27% increase from the last price of 5.28.
High203.0%16.00
Med127.3%12.00
Low89.4%10.00

Dividends

Historical dividend information is not available for LifeMD Inc.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Aug 07, 2024, LifeMD Inc reported 2nd quarter 2024 losses of -0.19 per share.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate-1.32%
LifeMD Inc reported annual 2023 losses of -0.70 per share on Mar 11, 2024.
Average growth rate+45.09%
More ▼

Revenue history & estimates in USD

Conversion Labs, Inc. had 2nd quarter 2024 revenues of 50.66m. This bettered the 48.25m consensus of the 5 analysts covering the company. This was 52.94% above the prior year's 2nd quarter results.
Average growth rate+9.19%
Conversion Labs, Inc. had revenues for the full year 2023 of 152.55m. This was 28.15% above the prior year's results.
Average growth rate+68.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.